Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
- Bristol Myers Squibb & Co (NYSE:BMY) has announced topline data from Phase 3 CheckMate -816 trial in patients with resectable stage IB to IIIA non-small cell lung cancer (NSCLC).
- The trial evaluated Opdivo (nivolumab) plus chemotherapy compared to chemotherapy alone as neoadjuvant treatment.
- The study met the primary endpoint of improved event-free survival (EFS). Opdivo/Chemo combo showed a statistically significant and clinically meaningful improvement in EFS compared to chemotherapy alone.
- This combination previously showed a significant improvement of pathologic complete response (pCR), the trial's other primary endpoint.
- The Company will complete a full evaluation of the available CheckMate -816 data and share the results at an upcoming medical conference.
- Price Action: BMY shares are up 0.60% at $59.80 during the market session on the last check Monday.
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!